| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Alaunos Therapeutics, Inc.
13D/A
TCRT · 98973P309
|
8.6% |
3/5/2026
Event 2/24/2026
|
||||
| Price Adrian | 8.6% | |||||
| Chris Butterworth | 0.5% | |||||
| Richard Jones | 0.7% | |||||
| Edward Jones | 0.5% | |||||
| Gareth Downing | 0.9% | |||||
| Richard Kotey | 0.6% | |||||
| Chris Cole | 0.7% | |||||
| Arif Chaudrey | 0.3% | |||||
| Emma Babb | 0.5% | |||||
| Colin Craig | 0.3% | |||||
| John Nicholls | 0.8% | |||||
| Carl Ware | 0.1% | |||||
| Andrew Turner | 0.6% | |||||
| Matthew Robbins | 0.5% | |||||
| Phillip James Stead | 0.5% | |||||
| Stephen Hennessy | 0.3% | |||||
| Greg Arnold | 0.5% | |||||
| Michelle Douglas | 0.4% | |||||
| HexagonONE Ltd | 0% | |||||
| Alimenta Holding Limited | 0% | |||||
| Krakatau Holding Limited | 0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.